9969.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 11:08):

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases...

Stats
Šios dienos apimtis	2.93M
Vidutinė apimtis	3.52M
Rinkos kapitalizacija	6.76B
EPS	HKD0 ( 2022-03-22 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-11.27
ATR14	HKD0.00500 (0.11%)

Tūris Koreliacija

Ilgas: 0.03 (neutral)

Trumpas: -0.92 (very strong negative)

Signal:(35.002) Neutral

InnoCare Pharma Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

InnoCare Pharma Ltd Koreliacija - Valiuta/Žaliavos

-0.70
( moderate negative )

-0.59
( weak negative )

0.00
( neutral )

-0.60
( weak negative )

0.66
( moderate )

0.80
( strong )

InnoCare Pharma Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	HKD738.54M
Bruto pelnas:	HKD610.10M (82.61 %)
EPS:	HKD-0.370

FY	2023
Pajamos:	HKD738.54M
Bruto pelnas:	HKD610.10M (82.61 %)
EPS:	HKD-0.370

FY	2022
Pajamos:	HKD625.40M
Bruto pelnas:	HKD482.01M (77.07 %)
EPS:	HKD-0.590

FY	2021
Pajamos:	HKD1.04B
Bruto pelnas:	HKD977.37M (93.70 %)
EPS:	HKD-0.0500

Financial Reports:

No articles found.

InnoCare Pharma Ltd

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.